The earnings call presented a strong positive outlook with significant revenue growth, successful adoption of Amtagvi, and strategic restructuring to improve profitability. Despite increased expenses and a setback in European regulatory strategy, the overall momentum and achievements outweigh the challenges.

Company Guidance -

Q3 2025

During the Iovance Biotherapeutics Second Quarter 2025 Financial Results Conference Call, the company provided several key metrics and updates. They reported total revenue of $60 million for the second quarter, marking a 22% growth over the previous quarter, with $54 million coming from Amtagvi infusions and $6 million from Proleukin. The company treated 102 commercial patients with Amtagvi during the quarter, surpassing 100 patients for the first time in a single quarter. Iovance reiterated its full-year 2025 revenue guidance of $250 million to $300 million and highlighted a gross margin of 31%, excluding noncash items. Operating expenses for the quarter were approximately $117 million, up from $102 million in the prior year, attributed to increased headcount and clinical trial costs. The company announced a strategic restructuring, including a workforce reduction of approximately 19%, expected to save over $100 million annually starting in the fourth quarter. Despite these changes, Iovance plans to maintain its clinical pipeline, aiming for a cash runway into the fourth quarter of 2026. The company also expressed confidence in achieving U.S. peak sales of $1 billion or more for Amtagvi, with opportunities for international expansion.

Strong Revenue Growth

Iovance reported $60 million in total revenue for Q2 2025, representing a 22% growth over the prior quarter, with $54 million from Amtagvi infusions and $6 million from Proleukin.

Amtagvi Adoption and Response Rates

Amtagvi adoption continues to grow, surpassing 100 patients treated in a single quarter for the first time, with a nearly 49% response rate among real-world patients and 61% in certain treatment settings.

Strategic Restructuring for Cost Savings

A strategic restructuring is expected to generate over $100 million in annual cost savings starting in Q4 2025, with a 19% workforce reduction planned for Q3 2025.

Manufacturing Improvements

Manufacturing success rates improved in Q2 2025, with lower patient drop-offs and out-of-spec rates. Turnaround time for manufacturing was reduced to 33 days.

Iovance Biotherapeutics (IOVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IOVA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.25 / -	-0.28	―	―	―
Aug 07, 2025	2025 (Q2)	-0.28 / -0.33	-0.34	2.94% (+0.01)	―
May 08, 2025	2025 (Q1)	-0.24 / -0.36	-0.42	14.29% (+0.06)	―
Feb 27, 2025	2024 (Q4)	-0.27 / -0.26	-0.45	42.22% (+0.19)	―
Nov 07, 2024	2024 (Q3)	-0.30 / -0.28	-0.46	39.13% (+0.18)	―
Aug 08, 2024	2024 (Q2)	-0.35 / -0.34	-0.47	27.66% (+0.13)	―
May 09, 2024	2024 (Q1)	-0.42 / -0.42	-0.5	16.00% (+0.08)	―
Feb 28, 2024	2023 (Q4)	-0.43 / -0.45	-0.64	29.69% (+0.19)	―
Nov 07, 2023	2023 (Q3)	-0.46 / -0.46	-0.63	26.98% (+0.17)	―
Aug 08, 2023	2023 (Q2)	-0.50 / -0.47	-0.63	25.40% (+0.16)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IOVA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$2.64	$2.11	-20.08%
May 08, 2025	$3.17	$1.75	-44.79%
Feb 27, 2025	$5.26	$4.24	-19.39%
Nov 07, 2024	$12.28	$10.58	-13.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Iovance Biotherapeutics (IOVA) report earnings?

Iovance Biotherapeutics (IOVA) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Iovance Biotherapeutics (IOVA) earnings time?

Iovance Biotherapeutics (IOVA) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IOVA EPS forecast?

IOVA EPS forecast for the fiscal quarter 2025 (Q3) is -0.25.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing